|Bid||25.22 x 4000|
|Ask||27.25 x 4000|
|Day's Range||26.85 - 27.50|
|52 Week Range||16.56 - 29.44|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||76.92|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Horizon Therapeutics plc (HZNP) today announced the launch of RAREisCommunity.com, a go-to resource for the more than 350 million people around the world living with rare disease. This website is the latest expansion of Horizon’s #RAREis™ program, which aims to elevate the voices, faces and experiences of the rare disease community. “One common theme that has arisen from our conversations with families and advocates in the rare disease community is the need to bring together resources and advice to help those living with rare diseases and their caregivers navigate through the challenges of life’s transitions,” said Ann Marie Bingo, associate director, patient advocacy, Horizon.
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million --
Horizon Therapeutics plc (HZNP) announced today that the company has won a Gold International CSR Excellence Award in the Large Business category for its partnership with Chicago-based school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be found here. Since 2016, Horizon’s partnership with MSA has focused on three areas of giving: infrastructure, programming and employee engagement.
Horizon Therapeutics plc (HZNP) announced today that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets. If approved by the FDA, this new dosage form would provide another option for patients, in addition to the currently available PROCYSBI delayed-release capsules. The capsules are FDA-approved for children one year of age and older and adults living with nephropathic cystinosis.
Horizon Therapeutics plc (HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com.
Horizon Therapeutics plc (HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $65 million in cash on hand, to redeem or prepay $625 million of its outstanding debt, consisting of (i) the outstanding $225 million principal amount of its 6.625% senior notes due 2023, (ii) the outstanding $300 million principal amount of its 8.75% senior notes due 2024 and (iii) $100 million of the outstanding principal amount of senior secured term loans under Horizon’s credit agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with the redemption and prepayment.
Horizon Therapeutics plc (HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $64 million in cash on hand, to redeem $525 million of its outstanding debt, consisting of the outstanding (i) $225 million principal amount of its 6.625% senior notes due 2023 and (ii) $300 million principal amount of its 8.75% senior notes due 2024, as well as to pay the related premiums, and fees and expenses, excluding accrued interest, associated with the redemption. The proposed redemption of Horizon’s existing senior notes is being conducted to further Horizon’s deleveraging strategy, to reduce interest expense and to extend the maturity of its debt obligations to improve its capital structure.
Horizon Therapeutics plc announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational medicine teprotumumab for the treatment of active thyroid eye disease .
Today marks the launch of a new patient empowerment and disease education initiative called Eyes on Graves’, created to bring attention, education and resources to people living with Graves’ disease and/or thyroid eye disease (TED). In time for Graves’ Disease Awareness Month in July, Eyes on Graves’ was created through a new collaboration called the Graves’ and TED Council – a group of people living with both diseases and their loved ones whose mission is to raise awareness and understanding of Graves’ disease and TED among physicians, patients and caregivers, leading to improved care and patient support. Eyes on Graves’ is supported by the Graves’ Disease and Thyroid Foundation (GDATF) and Horizon Therapeutics.
Horizon Therapeutics plc (HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout. Treatment with biologic medicines can, in some patients, trigger the body’s immune system to develop anti-drug antibodies. Immunomodulators, such as methotrexate, are often co-prescribed with biologics to help reduce this reaction.
Horizon Therapeutics plc (HZNP) is elevating the dialogue on gout within the medical and scientific community during the Annual European Congress of Rheumatology (EULAR 2019) with a series of data presentations on gout and its systemic implications. Oral and poster presentations reinforce the increasingly robust evidence linking gout to renal and cardiovascular health risks and raise important clinical considerations in monitoring and tracking patient status beyond joint health over time. “Across a number of independent evaluations, we’re finding important links between gout and other organ system diseases,” said Jeffrey Kent, M.D., senior vice president, medical affairs and outcomes research, Horizon.
Horizon Therapeutics plc , today announced that the company will participate in the following conference in June:
Horizon Therapeutics plc (HZNP) in partnership with Invitae Corporation (NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people who may have a UCD, including their family members. Horizon’s support of the UCD Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.
Horizon Therapeutics plc (HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “Best Workplaces in Chicago” list. “We are proud to be recognized as one of the Best Workplaces in Chicago for the third consecutive year,” said Irina Konstantinovsky, executive vice president, chief human resources officer, Horizon.
Horizon Therapeutics plc (HZNP) today announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease. Through a mix of thought-provoking visuals, expert videos and clinical data, the campaign is designed to inform a modern dialogue about the impact of gout. The goal is to specifically advance the understanding of the complex relationship between pain resolution and gout progression, given the unique mechanism that resolves acute pain in gout often results in patients delaying discussions with the physician.
Horizon Therapeutics plc (HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary. Tina will be honored today at the 30th annual Woman of the Year event in New York. The HBA is the leading not-for-profit global organization committed to furthering the advancement and impact of women in healthcare worldwide.
-- First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent; First-Quarter 2019 GAAP Net Loss of $32.9 Million; Adjusted EBITDA of $88.4 Million --
Horizon Therapeutics plc (HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees. The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4). Horizon Therapeutics plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases.
-- Efficacy Demonstrated Across Measures Not Addressed by Current Therapies --
Horizon Pharma plc (HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption Fund to help facilitate global adoptions of children with rare diseases. Children awaiting adoption with rare diseases often go untreated or receive minimal treatment, and many face life in a long-term care facility or nursing home, according to Gift of Adoption. The #RAREis Adoption Fund supports Gift of Adoption’s mission to provide financial assistance to complete the final steps of adoption of at-risk children.
Horizon Pharma plc today announced that it will present additional results from its Phase 3 confirmatory clinical trial evaluating teprotumumab for the treatment of active thyroid eye disease at the 2019 American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Congress.
Horizon Pharma plc (HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to Work® and FORTUNE Magazine. The company has also been awarded a 2019 Best Places to work in Chicago designation by Crain’s Chicago Business.
Horizon Pharma plc (HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and replay may be accessed at http://ir.horizon-pharma.com.
Horizon Pharma plc (HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted. The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with Nasdaq Listing Rule 5635(c)(4).
Horizon Pharma plc (HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA). PR News’ CSR Awards celebrate organizations committed to making the world a better place through innovative corporate social responsibility initiatives in the past 12 months, recognizing both the communications efforts surrounding a CSR initiative and the initiative itself. Since 2016, Horizon has partnered with MSA which focuses on pairing strong social emotional learning with a rigorous college preparatory curriculum emphasizing science, technology, math, engineering and the arts.